Patent ID: 11926642
Assignee: PFIZER INC.
Field: Organic fine chemistry (Chemistry)
Classification: CPC C  A | IPC A  C

Claim 11:
12. The pharmaceutical composition of claim 11 wherein:
a) the pharmaceutically acceptable salt is sodium;
b) the molar ratio of the sodium counterion to the (3S)-3-({N-[(4-methoxy-1H-indol-2-yl)carbonyl]-L-leucyl}amino)-2-oxo-4-[(3S)-2-oxopyrrolidin-3-yl]butyl dihydrogen phosphate in the pharmaceutically acceptable salt is approximately 0.5:1 to approximately 2:1;
c) the buffering agent is citric acid; and
d) the molar ratio of (3S)-3-({N-[(4-methoxy-1H-indol-2-yl)carbonyl]-L-leucyl}amino)-2-oxo-4-[(3S)-2-oxopyrrolidin-3-yl]butyl dihydrogen phosphate to citric acid is approximately 2:1 to approximately 10:1.